Pink Sheet is part of Informa PLC

This site is operated by a business or businesses owned by Informa PLC and all copyright resides with them. Informa PLC’s registered office is 5 Howick Place, London SW1P 1WG. Registered in England and Wales. Number 8860726.

This copy is for your personal, non-commercial use. For high-quality copies or electronic reprints for distribution to colleagues or customers, please call +44 (0) 20 3377 3183

Printed By


Blumenthal to lead U.S. health IT expansion

Executive Summary

HHS names David Blumenthal, most recently director of the Institute for Health Policy at the Massachusetts General Hospital/Partners Health Care System in Boston, as the national coordinator for health information technology. In this role, Blumenthal is tasked with implementing a nationwide health IT infrastructure, a daunting task based on results of small-scale rollouts (1"The Pink Sheet," March 2, 2009, p. 36). Blumenthal was a senior health advisor to President Obama during the campaign; he also has ties to Sen. Ted Kennedy, D-Mass., as a staffer on the Subcommittee on Health and Scientific Research in the 1970s. Blumenthal appeared on a preliminary list of candidates for FDA commissioner, but it was expected that he would land somewhere else within the administration (2"The Pink Sheet," Nov. 3, 2008, p. 25)

You may also be interested in...

Health IT Not “Low-Hanging Fruit” In Health Reform, Some Experts Say

Despite President Barack Obama and others calling health information technology "low-hanging fruit" in the context of comprehensive health care reform, some IT experts and even some in government see it as a more complex problem to solve

Adoption Of E-Health Records Gets Stimulus Of Medicare Rewards, Penalties

A program to bring about wider adoption of health information technology in physicians' offices is mirroring the conceptual framework of rewarding and penalizing physicians through Medicare payments that was used to promote adoption of electronic prescribing

US FDA Races To List Essential Medicines For Domestic Manufacture By White House Deadline

With list due 4 November, there may not be time for public comment. Meanwhile, where will biopharma find fill/finish capacity?





Ask The Analyst

Please Note: You can also Click below Link for Ask the Analyst
Ask The Analyst

Your question has been successfully sent to the email address below and we will get back as soon as possible. my@email.address.

All fields are required.

Please make sure all fields are completed.

Please make sure you have filled out all fields

Please make sure you have filled out all fields

Please enter a valid e-mail address

Please enter a valid Phone Number

Ask your question to our analysts